RT Journal Article
SR Electronic
T1 Overview of the First NRG-NCI Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy (RPT)
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP jnumed.120.255547
DO 10.2967/jnumed.120.255547
A1 Emilie Roncali
A1 Jacek Capala
A1 Stanley H Benedict
A1 Gamal Akabani
A1 Bryan Bednarz
A1 Vikram Bhadrasain
A1 Wesley E. Bolch
A1 Jeff Buchsbaum
A1 Bonnie N. Clarke
A1 Norman Coleman
A1 Yuni K Dewaraja
A1 Eric C. Frey
A1 Michael Ghaly
A1 Joseph Grudzinski
A1 Robert F Hobbs
A1 Roger W. Howell
A1 John Laurence Humm
A1 Charles Kunos
A1 Steven M. Larson
A1 Frank I Lin
A1 Mark T. Madsen
A1 Saed Mirzadeh
A1 David L. Morse
A1 Daniel A Pryma
A1 George Sgouros
A1 Sara St. James
A1 Richard L. Wahl
A1 Ying Xiao
A1 Pat B. Zanzonico
A1 Katherine B. Zukotynski
YR 2020
UL http://jnm.snmjournals.org/content/early/2020/12/04/jnumed.120.255547.abstract
AB In 2018, the National Cancer Institute (NCI) and the NRG Oncology partnered for the first time to host a joint Workshop on Systemic Radiopharmaceutical Therapy (RPT) to specifically address issues and strategies of dosimetry for future clinical trials. The workshop focused on (1) current dosimetric approaches for clinical trials, (2) strategies under development that would provide optimal dose reporting, and (3) future desired/optimized approaches for the new and novel emerging radionuclides and carriers in development. In this proceedings, we review the main approaches that are applied clinically to calculate the absorbed dose: These include absorbed doses calculated over a variety of spatial scales including organ, suborgan, and voxel, all achievable within the Medical Internal Radiation Dose (MIRD) schema (S-value) can be calculated with analytic methods or Monte Carlo methods, the latter in most circumstances. This proceeding will also contrast currently available methods and tools with those used in the past, to propose a pathway whereby dosimetry helps the field by optimizing the biological effect of the treatment and trial design in the drug approval process to reduce financial and logistical costs. We will also discuss the dosimetric equivalent of biomarkers to help bring a precision medicine approach to RPT implementation-when merited by evidence collected during early-phase trial investigations. Advances in the methodology and related tools have made dosimetry the optimum biomarker for RPT.